Anxiety disorders (GAD, panic, social)

What changes during this transition

Anxiety disorders sit on top of one of the deepest standard-of-care stacks in psychiatry, and any honest peptide framing has to start by naming that. Cognitive behavioral therapy is Tier 1 for generalized anxiety disorder, panic disorder, and social anxiety disorder, with exposure therapy specifically Tier 1 for SAD and panic; the APA, NICE, and Canadian Anxiety Guidelines Initiative converge on CBT-plus-exposure as first-line non-pharmacological treatment, and the effect sizes are large and durable. Pharmacotherapy first-line is the SSRI class — sertraline, escitalopram, and paroxetine carry FDA approvals across GAD, panic, and SAD between them — with SNRIs (venlafaxine, duloxetine) as the second branch and buspirone as the GAD-specific non-benzodiazepine option. Pregabalin carries an EU GAD indication and is used off-label in the US. Propranolol is off-label for performance anxiety in social-anxiety subtypes. Hydroxyzine fills the short-term sedating-antihistamine slot. None of that is displaced by anything in the peptide library. The benzodiazepine epidemic is the load-bearing background to every anxiety-disorder conversation in 2026. The prolonged prescribing patterns of the 1990s through the 2010s — alprazolam, clonazepam, lorazepam, diazepam dispensed for chronic anxiety far past the intended short-term use window — produced a generation of patients carrying chronic benzodiazepine dependence, and the FDA's 2020 boxed-warning update on the entire benzodiazepine class emphasized dependence, misuse, and the seizure risk that comes with abrupt withdrawal. The clinical landscape has shifted toward benzodiazepine-sparing strategies wherever possible, and that shift is the editorial backdrop for why a non-sedating, non-dependence-producing anxiolytic with a real clinical evidence base draws attention — even when that evidence base is single-jurisdiction. Selank is the strongest peptide case on this axis and the strongest source-jurisdiction evidence case in the library for any indication where the US FDA has not approved. The Russian Ministry of Health 2009 registration as a 0.15% intranasal prescription medicine for generalized anxiety disorder and neurasthenia is the primary approved indication, with the Zozulya 2008 head-to-head trial against medazepam (n=62) showing comparable anxiolytic effect without sedation or dependence; the tier reflects the cross-jurisdictional replication gap rather than the quality of the Russian work. Oxytocin's anxiety case is concentrated in social anxiety disorder as an exposure-therapy augmenter — Guastella 2009, Labuschagne 2010 fMRI amygdala-modulation, Hofmann 2015 CBT-augmentation with mixed signal — with much thinner evidence in panic and essentially none in GAD. Kisspeptin is emerging specialist neuropsychiatric research-context territory built on limbic-circuit modulation imaging work, with no anxiety-disorder RCT as of 2026. B12-methylcobalamin earns a place as the rule-out: functional B12 deficiency (MMA and homocysteine confirm) can present with anxiety symptoms in metformin users, chronic PPI users, vegans, post-bariatric patients, and elderly populations, and ruling it out belongs in the workup before SSRI/SNRI/benzo escalation. What's not surfaced as a discovery card here: BPC-157. The community 'gut-brain axis for anxiety' framing rests on rodent stress-paradigm work and the broader healing-context literature, with zero published human anxiety trial in GAD, panic, social anxiety, or any DSM-5 anxiety indication. The substrate entry exists so /ask can answer honestly when users raise the claim, and the answer is honest about the gap; the discovery surface does not promote it. The peptides surfaced here are coordinated with a treating psychiatrist or anxiety-specialist clinician — none belong in self-directed protocols, and the CBT-plus-evidence-based-medication program is the dominant intervention in every case.